320 related articles for article (PubMed ID: 30337279)
1. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
[TBL] [Abstract][Full Text] [Related]
2. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
3. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
4. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
[TBL] [Abstract][Full Text] [Related]
5. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
6. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Alcantara MB; Tang WS; Wang D; Kaniowski D; Kang E; Dizman N; Chehrazi-Raffle A; Meza L; Zengin Z; Hall J; Hsu J; Egelston C; Moreira D; Horsager A; Pal SK; Kortylewski M
Front Immunol; 2023; 14():1274781. PubMed ID: 38259453
[TBL] [Abstract][Full Text] [Related]
7. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
[TBL] [Abstract][Full Text] [Related]
8. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
10. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
[TBL] [Abstract][Full Text] [Related]
11. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
13. Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells.
Adamus T; Hung CY; Yu C; Kang E; Hammad M; Flores L; Nechaev S; Zhang Q; Gonzaga JM; Muthaiyah K; Swiderski P; Aboody KS; Kortylewski M
Mol Ther Nucleic Acids; 2022 Mar; 27():611-620. PubMed ID: 35036069
[TBL] [Abstract][Full Text] [Related]
14. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
Zoglmeier C; Bauer H; Noerenberg D; Wedekind G; Bittner P; Sandholzer N; Rapp M; Anz D; Endres S; Bourquin C
Clin Cancer Res; 2011 Apr; 17(7):1765-75. PubMed ID: 21233400
[TBL] [Abstract][Full Text] [Related]
15. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
[TBL] [Abstract][Full Text] [Related]
16. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
17. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.
Moreira D; Sampath S; Won H; White SV; Su YL; Alcantara M; Wang C; Lee P; Maghami E; Massarelli E; Kortylewski M
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33232304
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
[TBL] [Abstract][Full Text] [Related]
19. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Fernandez-Rodriguez L; Cianciaruso C; Bill R; Trefny MP; Klar R; Kirchhammer N; Buchi M; Festag J; Michel S; Kohler RH; Jones E; Maaske A; Vom Berg J; Kobold S; Kashyap AS; Jaschinski F; Dixon KO; Pittet MJ; Zippelius A
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208130
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
